If you’re considering medical weight loss in the UK, two names dominate the conversation — GLP-1 receptor agonists (like Wegovy, Ozempic, and Mounjaro) and the emerging triple agonist Retatrutide. But which one is right for you?
This guide breaks down the differences, benefits, costs, and availability in the UK — helping you decide what best suits your health goals.
What Are GLP-1 Receptor Agonists?
GLP-1 medications (like semaglutide and tirzepatide) mimic a hormone in your body that helps regulate appetite and blood sugar. They’ve become widely used in the UK and US for type 2 diabetes and now — weight loss.
What Is Retatrutide?
Retatrutide is a newer class of drug that targets three hormone receptors: GLP-1, GIP, and glucagon. This triple action is designed to accelerate fat burning, reduce cravings, and improve insulin sensitivity even more than its predecessors.
Comparison Table – GLP-1 vs Retatrutide
| Feature | GLP-1 Drugs (Wegovy/Ozempic) | Retatrutide |
|---|---|---|
| Type | GLP-1 only | GLP-1 + GIP + Glucagon |
| Weight Loss (avg.) | 15–18% | 22–24% |
| FDA/UK Approved | Yes | No (in trials) |
| Side Effects | Nausea, constipation | Slightly more intense during titration |
| Availability | Private & NHS | Coming soon |
Cost Comparison in the UK
GLP-1 (Wegovy, Ozempic): £180–£300/month
Retatrutide: Projected at £350–£450/month (once approved)
Which One Is Right for You?
- Choose GLP-1 if you want something available now and clinically proven in the UK
- Choose Retatrutide (soon) if you have resistant fat, fatty liver, or want faster results